REG - Destiny Pharma PLC - Result of Annual General Meeting

Destiny PharmaAnnouncement

25/05/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230525:nRSY6865Aa&default-theme=true

RNS Number : 6865A  Destiny Pharma PLC  25 May 2023

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Result of Annual General Meeting

 

Brighton, United Kingdom - 25 May 2023 - Destiny Pharma plc (AIM: DEST), a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life-threatening infections, announces that
all resolutions proposed to shareholders at the Annual General Meeting held
earlier today were duly passed.

 

The full text of each resolution was included in the notice of the meeting
which was made available on the Company's website and posted to shareholders
on 27 April 2023. The results for the resolutions will shortly be available on
the Investors' section of the Company's website, www.destinypharma.com
(http://www.destinypharma.com) .

 

For further information, please contact:

 

Destiny Pharma plc

Dr Debra Barker, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0)20 7220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

Optimum Strategic Communications

Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper

+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

About Destiny Pharma

 

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has completed a positive Phase 2 clinical trial targeting the prevention of
post-surgical staphylococcal hospital infections including MRSA. It is also
co-developing SPOR-COV(TM), a novel, biotherapeutic product for the prevention
of COVID-19 and other viral respiratory infections and has earlier grant
funded XF drug research projects.

 

For further information on the Company, please
visit  https://www.destinypharma.com (https://www.destinypharma.com/)
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAAMBTMTTTBBJ